SIRT3 and hepatocellular carcinoma: The underexpression of sirtuin 3 in hepatocellular carcinoma promotes the lactylation of cyclin E2, which in turn promotes tumor progression, and sirtuin 3 is a potential therapeutic target for hepatocellular carcinoma (69).